Vitae Pharmaceuticals Inc (VTAE)

21.00
0.01 0.05
Prev Close 20.99
Open 20.99
Day Low/High 20.99 / 21.00
52 Wk Low/High 4.08 / 18.71
Volume 541.11K
Avg Volume 1.10M
Exchange
Shares Outstanding 28.84M
Market Cap 605.66M
EPS -2.00
Div & Yield N.A. (N.A)

Latest News

Allergan Continues Down 'Stepping Stone' Path With Two Deals

Allergan Continues Down 'Stepping Stone' Path With Two Deals

The pharmaceutical maker announced two deals Monday as a part of the JP Morgan health care conference.

Allergan Takes Biggest Step Yet in 'Stepping Stone' Strategy, Signs $2.9 Billion Breast Cancer Deal

Allergan Takes Biggest Step Yet in 'Stepping Stone' Strategy, Signs $2.9 Billion Breast Cancer Deal

The company announced Tuesday that it will acquire Acelity's LifeCell for $2.9 billion in cash.

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks add to gains on Wednesday afternoon after the Federal Reserve opts to leaves rates unchanged at its September meeting.

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks hold higher on Wednesday as investors await a policy decision from the Federal Reserve.

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock futures climb after the Bank of Japan makes moves to tackle deflation, while U.S. investors await a policy decision from their own central bank.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Vitae...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding The Fairness Of The Sale Of Vitae Pharmaceuticals, Inc. To Allergan Plc For $21.00 Per Share

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding The Fairness Of The Sale Of Vitae Pharmaceuticals, Inc. To Allergan Plc For $21.00 Per Share

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals (VTAE) Stock Downgraded at BMO Capital

Vitae Pharmaceuticals (VTAE) Stock Downgraded at BMO Capital

Vitae Pharmaceuticals' (VTAE) stock rating was reduced to 'market perform' at BMO Capital on Thursday morning.

VTAE Crosses Above Average Analyst Target

VTAE Crosses Above Average Analyst Target

In recent trading, shares of Vitae Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $16.60, changing hands for $20.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Vitae...

Vitae Pharmaceuticals (VTAE) Stock Downgraded on $639 Million Allergan Deal

Vitae Pharmaceuticals (VTAE) Stock Downgraded on $639 Million Allergan Deal

Stifel cut its rating on Vitae Pharmaceuticals (VTAE) stock on Wednesday after the company announced its $639 million takeover by Allergan (AGN).

Allergan's Dealmaking Continues With Vitae Takeout

Allergan's Dealmaking Continues With Vitae Takeout

The $639 million deal marks the the third purchase for Brent Saunders since early August.

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.

4 Big Stocks to Add to Your Buy List -- Plus 3 to Avoid

4 Big Stocks to Add to Your Buy List -- Plus 3 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Fear of Being Left Out Is Lifting Indices

Fear of Being Left Out Is Lifting Indices

The overall technical condition of the indices remains negative.

Allergan Is Doing All the Right Things

It is a matter of when, not if the market appreciates its potential.

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.

Vitae Pharmaceuticals (VTAE) Stock Soars on $639 Million Allergan Deal

Vitae Pharmaceuticals (VTAE) Stock Soars on $639 Million Allergan Deal

Vitae Pharmaceuticals (VTAE) announced Wednesday morning that it would be acquired by Allergan (AGN) for $639 million.

Stock Futures Edge Higher After a Rocky Three Days

Stock Futures Edge Higher After a Rocky Three Days

Stock futures edge higher on Wednesday as Wall Street appears to stabilize after three days of extreme swings.

Vitae Pharmaceuticals Enters Oversold Territory (VTAE)

Vitae Pharmaceuticals Enters Oversold Territory (VTAE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Vitae Pharmaceuticals Appoints Daniel M. Junius To Board Of Directors

Vitae Pharmaceuticals Appoints Daniel M. Junius To Board Of Directors

Bryan Roberts, Ph.D. steps down from board